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Abstract
Point-of-care tools are needed in sub-Saharan Africa (SSA) to improve pediatric Burkitt 
lymphoma (BL) diagnosis and treatment. We evaluated plasma Epstein-Barr virus (pEBV) DNA 
as a pediatric BL biomarker in Malawi. Prospectively enrolled children with BL were compared to 
classical Hodgkin lymphoma (cHL) and non-lymphoma diagnoses. Pediatric BL patients received 
standardized chemotherapy and supportive care. pEBV DNA was measured at baseline, mid-
treatment, and treatment completion. Of 121 assessed children, pEBV DNA was detected in 76/88 
(86%) with BL, 16/17 (94%) with cHL, and 2/16 (12%) with non-lymphoma, with proportions 
higher in BL versus non-lymphoma (p<0.001) and similar in BL versus cHL (p=0.69). If detected, 
median pEBV DNA was 6.1 log10copies/mL for BL, 4.8 log10copies/mL for cHL, and 3.4 
log10copies/mL for non-lymphoma, with higher levels in BL versus cHL (p=0.029), and a trend 
toward higher levels in BL versus non-lymphoma (p=0.062). pEBV DNA declined during 
treatment in the cohort overall and increased in several children before clinical relapse. Twelve-
month overall survival was 40% in the cohort overall, and for children with baseline pEBV 
detected, survival was worse if baseline pEBV DNA was ≥6 log10copies/mL versus <6 
log10copies/mL (p=0.0002), and also if pEBV DNA was persistently detectable at mid-treatment 
versus undetectable (p=0.041). Among children with baseline pEBV DNA detected, viremia was 
the only significant risk factor for death by 12 months in multivariate analyses (adjusted hazard 
ratio 1.35 per log10copies/mL, 95% CI 1.04–1.75, p=0.023). Quantitative pEBV DNA has 
potential utility for diagnosis, prognosis, and response assessment for pediatric BL in SSA.
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INTRODUCTION
Burkitt lymphoma (BL) is the most frequent childhood cancer in sub-Saharan Africa (SSA) 
and accounts for 50% of pediatric cancer in Malawi.1 Although it is highly curable in 
resource-rich settings with intensive chemotherapy, outcomes are much worse in SSA.2 
Epstein-Barr virus (EBV) is causally associated with the endemic form of the disease seen 
most commonly throughout the region, in which more than 90% of tumor specimens are 
positive for EBV.3,4 Additionally, EBV can be detected in peripheral blood in endemic BL. 
Studies from Tanzania, Uganda, and Kenya demonstrated elevated EBV loads in whole 
blood among children with BL,5–7 and a Brazil study demonstrated plasma EBV load 
declines were associated with chemotherapy response.8 In contrast, a study of Kenyan 
children with endemic BL found no association between EBV load in whole blood at 
presentation and survival.9 For other tumor types causally associated with EBV, plasma or 
whole blood EBV DNA has also shown potential utility as a biomarker, including classical 
Hodgkin lymphoma (cHL),10 HIV-associated non-Hodgkin lymphoma (NHL),11,12 natural 
killer/T-cell lymphoma,13 and nasopharyngeal carcinoma.14,15
In SSA, BL diagnosis is often based on fine needle aspiration (FNA) without 
immunohistochemistry (IHC) or molecular confirmation, leading to diagnostic 
inaccuracy.16–19 In addition to diagnostic challenges, SSA centers typically lack advanced 
imaging like computed tomography (CT) and fluorodeoxyglucose positron emission 
tomography (FDG-PET), which are routinely used for staging and risk stratification, and to 
assess treatment response in resource-rich settings. As a result, there exists immense unmet 
need for implementable point-of-care tools to improve diagnosis and treatment for children 
with BL in SSA, for whom balancing benefits and risks of cytotoxic chemotherapy is 
difficult in environments with low supportive care infrastructure and significant treatment-
related toxicity.
In this context, we hypothesized that plasma EBV DNA would be an implementable and 
valuable clinical biomarker for BL diagnosis and treatment in SSA, and undertook a study 
evaluating its utility for this purpose. Our evaluation was nested within a prospective 
longitudinal cohort of children with BL at a national teaching hospital in Malawi receiving 
standardized evaluation and treatment.
METHODS
Setting and population
Kamuzu Central Hospital (KCH) is located in the Malawian capital, Lilongwe, and receives 
cancer referrals from the northern and central regions, serving approximately 8–9 million 
people. Malawi has 10% HIV prevalence, 67% ART coverage, annual gross domestic 
product per capita of 343 US dollars, and Human Development Index rank of 173 out of 188 
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countries.20–22 The KCH Lymphoma Study is a prospective observational cohort initiated in 
June 2013. All patients with pathologically confirmed lymphoproliferative disorders are 
eligible to participate after informed consent. For these analyses, we focused on 
consecutively enrolled children <18 years with BL between June 1, 2013 and October 31, 
2015. To evaluate the performance of plasma EBV DNA specifically for BL diagnosis, we 
also compared children with BL to enrolled children with cHL, the second most common 
pediatric lymphoma in Malawi which is also causally associated with EBV, as well as to 
enrolled children initially suspected to have lymphoma but pathologically confirmed to have 
non-lymphoproliferative disorders.
Pathologic diagnosis
All enrolled cases were confirmed using a novel weekly telepathology consultative platform 
involving 2–4 pathologists in Malawi and the United States who rendered a consensus 
opinion, after review of cytology slides or hematoxylin and eosin stained tissue sections. 
This model has been described in detail previously and demonstrated excellent concordance 
with subsequent United States review.23–25 Manual IHC for biopsy specimens or centrifuged 
cell blocks was performed locally, including CD3, CD20, CD30, CD45, CD138, Ki-67, 
BCL2, and terminal deoxynucleotidyl transferase (TDT). Other stains including 
synaptophysin and AE1/AE3 were used to distinguish lymphomas from neuroendocrine or 
epithelial tumors respectively when morphology was uncertain. Although we sought to 
obtain tissue or centrifuged cell blocks whenever possible, given frequent abdominal 
presentations and difficulty obtaining tissue from visceral sites with no interventional 
radiology, along with limited pediatric surgery and anesthesia, diagnosis was often made via 
cytology alone as is typical in SSA. All specimens were then shipped to the United States 
for secondary hematopathologist review and diagnostic confirmation, using a larger panel of 
automated IHC stains, including CD3, CD15, CD20, CD30, and PAX5 as required.
Clinical care
A detailed description of baseline characteristics, treatment course and toxicities, follow-up, 
and survival for pediatric BL patients receiving care at our center has been published.26 
Briefly, children with BL were treated uniformly with prophase COP (cyclophosphamide, 
vincristine, prednisone) reduction, followed by six cycles of CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisone) administered every 21 days. Intrathecal treatment was 
administered with each chemotherapy cycle. Hematopoietic growth factors were not 
available, and supportive care and anti-infective prophylaxis were standardized. Stage was 
assigned and response assessed using physical exam, chest x-ray, and abdominal ultrasound. 
Presence of concurrent infections such as malaria was assessed at the treatment team’s 
discretion based on symptoms, but not systematically, and rapid point-of-care diagnostic 
tests and treatment for malaria were reliably available throughout the study period.
EBV assessment
EBV was assessed in tumors and serially collected plasma specimens. EBV was evaluated in 
tumors by EBV-encoded RNA in situ hybridization (EBER ISH) (Leica Biosystems, 
Wetzlar, Germany). For quantitative plasma EBV DNA, anticoagulated plasma was collected 
and cryopreserved at −80°C prior to cytotoxic treatment initiation, at mid-treatment (cycle 3 
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day 21), at treatment completion (cycle 6 day 21), and whenever possible at clinical relapse. 
All samples were shipped to the University of North Carolina at Chapel Hill where plasma 
EBV was measured using a real-time quantitative polymerase chain reaction (qPCR) assay 
performed at the University of North Carolina Vironomics Core with a linear detection range 
of 2.0–8.0 log10copies/mL. We used a primer pair targeting a conserved region of the EBV 
EBNA3C gene, details of which were previously described for the detection of EBV DNA 
and RNA.27,28 This assay targets position 88933-89033 of the EBVI reference genome 
(NC_007605) and positions 89735-89835 of the EBVII reference genome (NC_009334) to 
yield a small 100 bp amplicon, and is able to detect total as well as fragmented DNA. The 
targeted region is highly conserved across EBV isolates, and because the assay uses SYBR 
green as the method of detection, it can accommodate single nucleotide polymorphisms 
without loss of sensitivity, as we have shown for other targets using the same assay design.29 
Given our focus on evaluating clinical utility of a potentially implementable assay within the 
Malawi context, we did not conduct additional molecular investigations to distinguish 
encapsidated from non-encapsidated plasma EBV DNA.
Statistical analysis
Cohort characteristics were summarized using simple descriptive statistics. Plasma EBV 
DNA was analyzed using log10 transformed values. At baseline, we compared the proportion 
of children with detectable viremia and median viral loads across diagnostic groups. For 
children with BL, we analyzed changes in the proportion of children with detectable viremia 
and median viral loads during and after cytotoxic treatment. Proportions were compared 
using Fisher’s exact test and medians using Wilcoxon rank sum, and correlations assessed 
using Pearson’s correlation coefficient. Follow-up time was calculated from enrollment until 
progression or death, loss to follow-up, or administrative censoring on May 15, 2016. 
Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-
Meier methods, and the log-rank test was used to assess survival differences between 
groups. Cox proportional hazards were used to estimate bivariate and multivariate hazard 
ratios for OS and PFS. Given non-standardized criteria for response assessment for pediatric 
BL in SSA, and evaluation of response using relatively crude methods in Malawi where 
advanced imaging is not routinely available, we principally focused time-to-event analyses 
on OS as the clearer and more defensible clinical endpoint in our setting. Cause of death was 
determined by consensus review involving two study clinicians. All analyses were 
performed using STATA SE version 12.1 (College Station, Texas).
Ethical approval
The study was conducted in accordance with the Helsinki Declaration, after approval by the 
Biomedical Institutional Review Board of the University of North Carolina at Chapel Hill, 
the Protocol Review Committee of the Lineberger Comprehensive Cancer Center, and the 
Malawi National Health Sciences Research Committee.
RESULTS
Of 137 children enrolled during the study period, baseline plasma EBV DNA was assessed 
in 121 (88%), including 88/94 (94%) with BL, 17/18 (94%) with cHL, and 16/25 (64%) 
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with non-lymphoma diagnoses (Table 1). Non-lymphoma diagnoses with plasma EBV DNA 
assessed included children who were pathologically confirmed to have tuberculosis (n=4), 
rhabdomyosarcoma (n=3), Kaposi sarcoma (n=2), Wilm’s tumor (n=2), other infectious/
reactive lymphadenitis (n=2), acute myeloid leukemia (n=1), salivary gland tumor (n=1), and 
non-hematopoietic small round blue cell tumor (n=1). Among patients tested, plasma EBV 
DNA was detected in 76/88 (86%) children with BL, 16/17 (94%) children with cHL, and 
2/16 (12%) children with non-lymphoma diagnoses, with proportions being higher in BL 
versus non-lymphoma (p<0.001) and similar in BL versus cHL (p=0.69). If detected, median 
plasma EBV DNA level was 6.1 log10copies/mL [interquartile range (IQR) 4.9–6.9] for 
children with BL, 4.8 log10copies/mL (IQR 4.1–5.8) for cHL, and 3.4 log10copies/mL (IQR 
3.0–3.7) for non-lymphoma, with higher levels observed in BL versus cHL (p=0.029), and a 
trend toward higher levels in BL versus non-lymphoma (p=0.062) when detected.
Characteristics for 88 children with pathologically confirmed BL for whom baseline plasma 
EBV DNA was assessed are shown in Table 2, stratified by baseline plasma EBV detection. 
EBER ISH was available for 18 children (20%). Plasma EBV was detected in 12/12 patients 
with positive EBER ISH and 2/6 patients with negative EBER ISH (p=0.005), with median 
levels when detected 6.7 in EBER ISH positive cases versus 4.6 log10copies/mL in EBER 
ISH negative children (p=0.14). Additionally, children with detectable baseline plasma EBV 
were sicker, with worse Lansky performance status and trends toward lower albumin and 
higher lactate dehydrogenase (LDH). Baseline plasma EBV DNA levels were positively 
correlated with LDH (r=0.22, p=0.040).
During chemotherapy, plasma EBV DNA declined in most pediatric BL patients (Figure 1 
and Supplemental Figure). Compared with baseline, children had less frequently detectable 
plasma EBV DNA at mid-treatment (86% vs 65%, p=0.003) and completion (86% vs 70%, 
p=0.033). When detected, plasma EBV DNA levels also declined during cytotoxic treatment 
(median 6.1 log10copies/mL baseline vs 4.4 mid-treatment vs 3.4 completion), with 
significant differences between viremia levels at mid-treatment versus baseline, and 
completion versus baseline (p<0.0001 for both comparisons). Significant differences were 
not observed between mid-treatment and treatment completion, for either the proportion of 
children with detectable plasma EBV DNA or median viremia levels when detected. 
Although few children had assessable plasma for EBV DNA at clinical relapse, the 
proportion with detectable viremia was similar to mid-treatment and completion timepoints, 
but viremia level was higher at relapse when detected (median 5.2 log10copies/mL, p=0.068 
vs mid-treatment, p=0.014 vs completion). Additionally, three children had markedly 
elevated outlier plasma EBV DNA values at the completion timepoint as shown in Figure 
1A, all of whom had BL that was clinically refractory to first-line treatment and resulted in 
death within three months of CHOP completion, without plasma EBV DNA being 
subsequently assessed.
As of May 15, 2016, disease and vital status were known for 80/88 (91%) children after 
median follow-up of 13.2 months (IQR 9.3–26.9) among those not known to have died. For 
children who were untraceable by cellphone, four were from neighboring Mozambique and 
had traveled with their families to receive care in Malawi and subsequently returned home. 
Despite significant efforts to standardize care with dedicated pediatric oncology support, 
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outcomes in the cohort overall with anthracycline-based treatment were suboptimal with OS 
40% [95% confidence interval (CI) 29–51%] and PFS 31% (95% CI 21–41) at 12 months, 
and OS 28% (95% CI 18–40%) and PFS 27% (95% CI 17–38) at 24 months. Of 55 deaths in 
the cohort, 41 (75%) were attributed to relapsed or refractory BL on central adjudication and 
14 (25%) to treatment-related complications.
OS did not differ within the cohort based on baseline plasma EBV detection (Figure 2). 
However, among children with baseline plasma EBV detected, survival was significantly 
worse for patients with baseline level ≥6 log10copies/mL versus <6 log10copies/mL 
(p=0.0002). Additionally, after cytotoxic treatment initiation, survival was worse for children 
with persistent mid-treatment plasma EBV detection versus those without (p=0.041). 
Findings were similar as well in analyses using PFS as the primary outcome. During the 
study period, 15 confirmed episodes of clinical malaria were documented, and no 
differences were observed in baseline plasma EBV DNA detection or quantitative levels 
between children who developed malaria versus those who did not.
Risk factors for mortality by 12 months are shown in Table 3. In adjusted analyses in the 
cohort overall, mortality was associated with Lansky performance status <70 [adjusted 
hazard ratio (AHR) 2.38, 95% CI 1.02–5.59, p=0.046], increased LDH (AHR 1.02 per 100 
IU/L, 95% CI 1.00–1.03, p=0.015), and possibly age ≥9 years (AHR 1.89, 95% CI 0.98–
3.63, p=0.056). In adjusted analyses among only children with plasma EBV DNA detected 
at baseline, viremia level was the only significant risk factor for death by 12 months (AHR 
1.35 per log10copies/mL, 95% CI 1.04–1.75, p=0.023). Again, findings were similar in 
analyses using PFS as the primary outcome.
DISCUSSION
To our knowledge, this is the first study from SSA to systematically assess utility of plasma 
EBV DNA for pediatric BL diagnosis, prognosis, and response assessment. Study strengths 
include serial assessment of EBV DNA at pre-specified clinical timepoints, within a 
prospective cohort of children receiving standardized treatment with minimal loss to follow-
up. Additionally, high-quality pathologic diagnoses were rendered using a novel 
telepathology platform which is innovative for the region,23–25 comparison was made to 
simultaneously enrolled children with cHL and non-lymphoproliferative disorders, and 
detailed evaluation facilitated adjustment for other key BL prognostic variables.
With respect to diagnosis, frequent EBV DNA detection (86%) distinguished children with 
BL from those referred for clinical suspicion of lymphoma who were pathologically 
confirmed to have non-lymphoproliferative disorders (12%). Moreover, EBV DNA levels if 
detected distinguished children with BL (median 6.1 log10copies/mL) from those with cHL 
(median 4.8 log10copies/mL), the second commonest pediatric lymphoma in Malawi which 
is also associated with EBV. Scarcity of diagnostic pathology in SSA has been amply 
documented,30 and even where pathology services exist, diagnosis of BL and other 
lymphoproliferative disorders often relies on cytology with absent or limited IHC and absent 
molecular tools.16–19 As a result, studies in the region are invariably affected by small 
proportions of other aggressive NHL subtypes diagnosed as endemic BL, including 
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lymphoblastic lymphoma, diffuse large B-cell lymphoma, or sporadic EBV-negative BL, 
which also occurs in SSA albeit less frequently than endemic BL and typically among older 
children.26,31 In Lilongwe, we have made significant efforts to increase use of biopsies or 
centrifuged FNA cell blocks for IHC confirmation of BL diagnosis, but frequent visceral 
and/or abdominal presentations, limited interventional radiology, limited pediatric surgery, 
and limited pediatric anesthesia, often render cytologic diagnosis unavoidable despite these 
efforts. In such instances, plasma EBV DNA alone may not have sufficient utility to 
diagnose or exclude lymphoma and distinguish lymphoma subtypes, but could be included 
within composite diagnostic algorithms incorporating real-time pathologic, clinical, and 
laboratory data generated locally. We believe such an approach is more practical for SSA 
than tissue-based fluorescence in situ hybridization for MYC translocation to confirm all 
pediatric BL cases, and could substantially reduce current diagnostic uncertainties which 
remain a major issue for BL care and research throughout the region. IHC for MYC or 
Epstein-Barr nuclear antigen 1 (EBNA1) might also have applicability for improving local 
diagnostic accuracy. Indeed, with support from the National Cancer Institute Center for 
Global Health, we are now undertaking efforts to derive and validate a diagnostic score 
specifically for molecularly confirmed BL which incorporates plasma EBV DNA qPCR 
performed onsite in our Malawi laboratory, using a commercially available assay with our 
existing HIV RNA platform,32 along with age, anatomic site, symptom duration, LDH, and 
telepathology review. Moreover, analyzable DNA can be recovered from FNA specimens,33 
which might also allow EBV detection directly from cytology slides.
With respect to prognosis and response assessment, we observed markedly elevated plasma 
EBV DNA among children with BL at baseline with subsequent declines during 
chemotherapy, as observed in Brazil,8 and often increasing levels prior to clinical relapse. 
Among children with plasma EBV detected at baseline, outcomes were significantly worse 
for those with higher viremia, as well as those with persistent plasma EBV DNA at the 
midpoint of treatment. Additionally, baseline plasma EBV DNA was the only significant 
predictor of outcomes in multivariate analyses for these children, with each unit increase in 
log10copies/mL being associated with a 35% increased hazard of death by 12 months. 
Patients with baseline plasma EBV detected are arguably those children most likely to have 
truly endemic EBV-positive BL, as opposed to other aggressive NHL subtypes, given 
diagnostic challenges referenced above.
Our findings suggest EBV load monitoring could improve risk stratification and response 
assessment in SSA, particularly in light of the critical unmet need to optimize balance 
between treatment efficacy and toxicity for vulnerable, often malnourished children 
receiving chemotherapy in poor supportive care environments. Analogously, HIV RNA 
assessment is well established for antiretroviral therapy monitoring and early infant 
diagnosis in SSA,34 and existing qPCR instruments could likely be adapted for EBV. In 
resource-rich settings, EBV DNA assessment has greater utility in plasma than peripheral 
blood mononuclear cells (PMBCs) for EBV-positive lymphoproliferative disorders.35 In 
Kenyan children, the strength of association between cellular and plasma EBV DNA varies 
between healthy children and those with BL, which may also have implications for post-
treatment monitoring during remission.36 Moreover, assays utilizing plasma or whole blood 
can be successfully implemented even in resource-limited settings.37
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Despite efforts to intensify treatment at our center including anthracycline-based 
chemotherapy with pediatric oncology support, given historical experience with frequent 
relapses after less intensive regimens, outcomes were suboptimal as previously described, 
with the majority of deaths due to relapsed or refractory BL on central adjudication.26 This 
is further supported by persistent EBV detection in 70% of children even after chemotherapy 
completion, suggesting that despite treatment intensification, achievable cumulative dose 
and dose intensity using this approach in our environment were insufficient to eradicate 
disease and cure children with advanced, aggressive BL. Better therapeutic strategies are 
therefore essential, which we are actively pursuing with regional colleagues through the 
National Cancer Institute Burkitt Lymphoma Trial Network, including greater incorporation 
of systemic methotrexate into front-line chemotherapy as has been reported by other groups 
to result in better outcomes.38–41 Incorporating newer non-cytotoxic agents, like the anti-
CD20 monoclonal antibody rituximab, should also be an urgent priority especially in 
settings where a cytotoxic ‘ceiling’ is imposed by limited supportive care, rendering more 
intensive regimens from high-income countries impractical.
Apart from diagnostic and treatment challenges intrinsic to the Malawi setting, which we 
continue to address but which remain substantial, limitations of our study include referral 
bias at a national teaching hospital, assigning cause of death based on inference after 
centralized review, non-systematic assessment of concurrent malaria, and lack of distinction 
between encapsidated and non-encapsidated plasma EBV DNA. Additionally, plasma EBV 
DNA assessments were missing in some children at disease progression, and not performed 
after treatment completion in children without subsequent disease progression, making it 
difficult to clearly distinguish different plasma EBV DNA trajectories among groups of 
children defined by their chemotherapy response.
To conclude, quantitative plasma EBV DNA demonstrated potential utility for diagnosis, 
prognosis, and response assessment in a prospective pediatric BL cohort in Malawi receiving 
standardized anthracycline-based treatment. These findings require validation in larger 
regional studies, but suggest plasma EBV DNA may be an implementable and valuable 
biomarker for improving outcomes, through better diagnosis and more effectively risk-
stratified and response-guided therapy for children with BL in SSA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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cHL classical Hodgkin lymphoma
COP cyclophosphamide vincristine, prednisone




EBER ISH Epstein-Barr virus-encoded ribonucleic acid in situ hybridization
EBV Epstein-Barr virus
FDG-PET fluorodeoxyglucose positron emission tomography
FNA fine needle aspirate
IHC immunohistochemistry
IQR interquartile range
KCH Kamuzu Central Hospital




pEBV plasma Epstein-Barr virus
PFS progression-free survival
qPCR quantitative polymerase chain reaction
RNA ribonucleic acid
SSA sub-Saharan Africa
TDT terminal deoxynucleotidyl transferase
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This is the first study to systematically assess plasma EBV DNA for pediatric Burkitt 
lymphoma diagnosis, prognosis, and response assessment in sub-Saharan Africa. Plasma 
EBV DNA may be an implementable biomarker to facilitate better diagnosis and risk-
stratified, response-guided therapy for this challenging population in the region.
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Figure 1. Quantitative plasma Epstein-Barr virus DNA during pediatric Burkitt lymphoma 
treatment in Lilongwe, Malawi
EBV = Epstein-Barr virus. IQR = interquartile range.
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Figure 2. Kaplan-Meier overall survival for pediatric Burkitt lymphoma in Lilongwe, Malawi
(A) Overall cohort with 95% confidence intervals. (B) Stratified by baseline plasma Epstein-
Barr virus DNA detection. (C) Stratified by baseline plasma Epstein-Barr virus DNA level if 
detected. (D) Stratified by mid-treatment plasma Epstein-Barr virus DNA detection. OS = 
overall survival. CI = confidence interval. pEBV = plasma Epstein-Barr virus.
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Table 2
Baseline characteristics of pathologically confirmed pediatric Burkitt lymphoma patients in Lilongwe, 
Malawi, stratified by plasma EBV DNA detection at diagnosis.
pEBV DNA+ (n=76) pEBV DNA− (n=12) P value
Female, n (%) 27 (36) 3 (25) 0.74
Age, years, median (IQR) 9.1 (7.1–12.1) 10.8 (7.0–12.6) 0.51
Stage III/IV, n (%) 60 (78) 8 (67) 0.46
HIV positive, n (%) 2 (3) 0 (0) 1.00
Histology diagnosisA, n (%) 21 (28) 4 (33) 0.74
Tumor EBER ISH positiveB, n (%) 12/14 (86) 0/4 (0) 0.005
UnderweightC, n (%) 27 (37) 5 (42) 0.76
Lansky performance status ≤70, n (%) 57 (76) 5 (42) 0.034
White blood cells, 103/μL, median (IQR) 8.7 (6.6–12.9) 9.4 (7.6–11.3) 0.70
Absolute neutrophil count, 103/μL, median (IQR) 4.3 (2.6–7.2) 4.4 (2.8–6.9) 1.00
Hemoglobin, g/dL, median (IQR) 10.2 (8.8–11.7) 10.4 (8.5–12.6) 0.86
Platelets, 103/μL, median (IQR) 414 (270–570) 480 (307–567) 0.70
Albumin, g/dL, median (IQR) 3.3 (2.9–3.7) 3.7 (3.2–4.6) 0.078
Lactate dehydrogenaseD, IU/L, median (IQR) 668 (394–1,535) 365 (256–983) 0.12
pEBV = plasma Epstein-Barr virus. EBER ISH = Epstein-Barr virus encoded RNA in situ hybridization. IQR = interquartile range.
A
Diagnosis for non-histology cases was based on consensus telepathology review of cytology without tissue or cell block.
B
EBER ISH was only available for a subset of histology specimens evaluated in the United States.
C
Underweight was defined as weight-for-age z-score <−2 if <5 years or body mass index (BMI) z-score <−2 if ≥5 years.
D
Laboratory upper limit of normal was 250 IU/L.
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